Fact Sheet Juno Continuation Fund – March 2025



This is a marketing communication

MANAGER COMMENTARY

After a successful start for the European stock markets and for the fund in January, sentiment changed radically in March. Initially, there were nice price reactions to the better-than-expected figures and prospects announced by various portfolio companies (BioMérieux, VAT, Campari), but these price gains quickly disappeared thereafter. The American government announced intended import duties. Although the details are still unclear, this led to great unrest among investors. Also, the German government announced that it intends to make huge investments in defense and infrastructure. The expectation is that German government debt will increase rapidly. As a result, European long-term interest rates rose sharply, which had a severely negative impact on share prices. Despite the fact that we had reduced some positions earlier in the year and held almost 20% in cash, the combination of a possible trade war and higher interest rates hit our growth stock portfolio disproportionately. For example, Amplifon, Straumann, Bachem, Galderma, Rational, ICON and Tecan all fell more than 10% during the month. Only Scout24 and Carl Zeiss were able to close the month with a small plus. These sharp price declines created a serious disconnect between fundamentals and valuation. We can use the available cash position to better benefit from the recovery.

FUND PROFILE


Fund size	€ 43 million
Net asset value*	€ 83.85
Equity exposure	81%
# Portfolio companies	16
Weighted average market cap	€ 10.5 billion

^{*} per participation

Initial investment from	€150,000			
Add-ons from	€25,000			
Management Fee	1.2% p/a			
Performance Fee	10%			
High Water Mark	Perpetual			
	(€119.65; 31/7/21)			
Entry Fee	0.75%			
Exit Fee	0.25%			
TER	1.32% (2023)			
Legal Status	Mutual Fund			
Fund Currency	EUR			
Valuation	Monthly			
Inception	February 1, 2020			
Reporting	Net			
Licence	AIFMD			
Depositary	State Street Bank			
ISIN	NL0014157836			
Bloomberg	JUNOCNF NA			
Reuters	68608217			

PERFORMANCE UP TO MARCH 31, 2025

Past results are no quarantee for future performance



Source: Juno Investment Partners B.V., monthly net asset value, excluding entry and exit fees; MSCI

HISTORICAL PERFORMANCE IN FIGURES

	1 mo	YTD	1 yr	3 yrs	5 yrs	since inception
Juno Continuation Fund	-7.0%	-2.6%	-11.1%	-14.6%	-4.5%	-16.1%
MSCI Europe Mid Cap Euro (Ne	-2.7%	4.9%	9.4%	16.9%	79.0%	34.7%

ESG-PROFILE

SFDR-classification: Article 8

"Article 8"-products promote social and/or ecological characteristics, but do not have sustainable investing as their main objective.

For more information on Juno's sustainability policy, click here. Juno Investment Partners' Principal Adverse Impact (PAI) statement can be found here.

PORTFOLIO - TOP 5

Name Sector
Novozymes A/S Chemicals

Biomerieux SA Health Care Equipment & Supplies


ALK-Abello A/S Pharmaceuticals

Bachem Holding AG Life Sciences Tools & Services
Scout 24 AG Interactive Media & Services


PORTFOLIO - CURRENCY



PORTFOLIO - SECTORS



PORTFOLIO - COUNTRIES



STRATEGY

Juno invests in highly profitable listed companies, with predictable earnings growth and preferably with management or a (founding) family as their main shareholders. Listed European family-owned companies operate with a longer term perspective and are more successful than non-family-owned companies.

Juno aims to achieve capital growth by investing in a highly concentrated portfolio of European companies. Selection takes place based on its proprietary fundamental, bottom-up analysis and on-site visits.

A high or rising return on capital and large free cash flows are good indicators of strong companies that we are interested in. We invest with a time horizon of 3 to 5 years.

The Juno Continuation Fund focuses on companies with a market cap between €4 billion and €20 billion at the moment of initial investment.

I) Source: Stiftung Familienunternehmen, A. Gregorič, M.S. Rapp, I. Requejo "Listed Family Firms in Europe, Relevance, Characteristics and Performance", 2022.

DISCLAIMER

Attention: This is a marketing communication. The information about financial markets or specific financial instruments in this document is solely intended to provide you with information about the Juno portfolio management team's view on the financial markets. This information is not an investment recommendation, nor an offer or invitation to buy or sell a financial instrument. The decision to participate in this investment fund should be taken solely on the basis of the prospectus and the key information document. You can consult these documents under 'Fund Documents' on the Fund's web page.

There are risks associated with this investment. The value of your investment may fluctuate, and past performance is no guarantee of future performance. The fund invests in stocks and stocks have a higher risk profile than bonds. The fund invests in a limited number of companies, which may lead to stronger fluctuations in the fund's net asset value than would have been the case if the fund were less concentrated. For an overview of the risks of this fund, we refer to the risk section included in the prospectus.

Juno obtains its information from sources deemed reliable, such as annual reports and other official publications, and has taken every care to ensure that the information on which it bases its view is not incorrect or misleading. The net returns presented in this communication are based on the

